Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD).

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by growth of kidney cysts and glomerular filtration rate (GFR) decline. Metformin was found to impact cystogenesis in preclinical models of polycystic disease, is generally considered safe and may be a promising candidate for clinical investigation in ADPKD. In this phase 2 two-year trial, we randomly assigned 97 patients, 18-60 years of age, with ADPKD and estimated GFR over 50 ml/min/1.73 m2, in a 1:1 ratio to receive metformin or placebo twice daily.

Source: Kidney International - June 26, 2021 Category: Urology & Nephrology Authors: Ronald D. Perrone, Kaleab Z. Abebe, Terry Watnick, Andrew Althouse, Kenneth R. Hallows, Christina M. Lalama, Dana C. Miskulin, Stephen L. Seliger, Cheng Tao, Peter C. Harris, Kyongtae Ty Bae Tags: clinical trial Source Type: research